Pulmatrix, Inc. (PULM) company profile
Close on Nov 17, 2026Market cap $5.00MP/E –Yield –
About Pulmatrix
Pharmaceutical Preparations, SIC 2834
Pulmatrix, Inc. is a biopharmaceutical company focused on developing inhaled therapeutic products to prevent and treat central nervous system disorders and serious respiratory diseases. Using its proprietary dry powder delivery technology platform, iSPERSE, the company designs small, dense, and dispersible particles that deliver small or large molecule drugs into the airways without reliance on conventional lactose blends. Its proprietary clinical product pipeline includes PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease, and PUR1900 for allergic bronchopulmonary aspergillosis in patients with asthma or cystic fibrosis.
The company operates its corporate office in Framingham, Massachusetts. Following a strategic review, the company agreed to merge with Cullgen Inc. and has paused active clinical development across its product pipeline while exploring opportunities to license or monetize its assets and delivery platform.
Summary of the business section of Pulmatrix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pulmatrix, Inc.
- Founded
- 2013
- Headquarters
- Framingham, MA
- Address
- 945 Concord Street, Suite 1217 01701
- Phone
- (888) 355-4440
- Website
- pulmatrix.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- PULM
- Former tickers
- RTGN until Aug 14, 2015
- Exchange
- Nasdaq
- IPO date
- Mar 21, 2014
- Shares outstanding
- 4M, Aug 13, 2026
- Public float
- $25.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Mar 1, 2022; 1-for-10 reverse, Feb 6, 2019; 1-for-2.5 reverse, Jun 16, 2015
- SEC CIK
- 1574235
- CUSIP
- 74584P301
- ISIN
- US74584P3010
- FIGI
- BBG003TH2QL1
- Share class FIGI
- BBG003TH2QM0
- LEI
- 5299002RHCRZ9ST3GN42
- EIN
- 46-1821392
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Pulmatrix's leadership is listed in its proxy statement, last filed Nov 8, 2024.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 21, 2014
- Offer price
- $7.25
- Securities offered
- 2,650,000
- Gross proceeds
- $19.21M
- Exchange
- Nasdaq
- First trading day
- Mar 21, 2014
- First-day close
- $7.250.0%
- Lock-up ends (est.)
- Sep 17, 2014
“Per Unit Total Public offering price $ 7.25 $ 19,212,500 Underwriting discounts and commissions (1) $ 0.58 $ 1,537,000 Offering proceeds to us, before expenses $ 6.67 $ 17,675,500 (1) Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Dawson James Sec”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had two full-time employees, both of whom were engaged in full-time administrative activities.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?